Journal of Pediatrics, The, ISSN 0022-3476, 2012, Volume 161, Issue 4, pp. 723 - 728.e2
Objective To characterize the natural history of intestinal failure (IF) among 14 pediatric centers during the intestinal transplantation era. Study design The...
Pediatrics | MORTALITY | MANAGEMENT | EFFICACY | SHORT-BOWEL SYNDROME | LIPID EMULSION | INFANTS | PREVENTION | PARENTERAL-NUTRITION | PEDIATRICS | FISH-OIL | TRANSPLANTATION | Intestinal Diseases - surgery | Prognosis | Humans | Gastroschisis - epidemiology | Infant | Male | Enterocolitis, Necrotizing - epidemiology | Intestinal Diseases - therapy | Hirschsprung Disease - epidemiology | Intestinal Diseases - mortality | Female | Intestinal Volvulus - epidemiology | Intestinal Atresia - epidemiology | Retrospective Studies | Intestines - transplantation | Parenteral Nutrition | Intestinal Diseases - epidemiology | Consortia | Universities and colleges | Children's hospitals | parenteral nutrition | intestinal transplantation | PIFCon | short bowel syndrome | Intestinal failure
Pediatrics | MORTALITY | MANAGEMENT | EFFICACY | SHORT-BOWEL SYNDROME | LIPID EMULSION | INFANTS | PREVENTION | PARENTERAL-NUTRITION | PEDIATRICS | FISH-OIL | TRANSPLANTATION | Intestinal Diseases - surgery | Prognosis | Humans | Gastroschisis - epidemiology | Infant | Male | Enterocolitis, Necrotizing - epidemiology | Intestinal Diseases - therapy | Hirschsprung Disease - epidemiology | Intestinal Diseases - mortality | Female | Intestinal Volvulus - epidemiology | Intestinal Atresia - epidemiology | Retrospective Studies | Intestines - transplantation | Parenteral Nutrition | Intestinal Diseases - epidemiology | Consortia | Universities and colleges | Children's hospitals | parenteral nutrition | intestinal transplantation | PIFCon | short bowel syndrome | Intestinal failure
Journal Article
Journal of Pediatrics, The, ISSN 0022-3476, 2015, Volume 167, Issue 1, pp. 29 - 34.e1
Objectives In a large cohort of children with intestinal failure (IF), we sought to determine the cumulative incidence of achieving enteral autonomy and...
Pediatrics | MANAGEMENT | SHORT-BOWEL SYNDROME | PEDIATRIC-PATIENTS | ADAPTATION | INFANTS | PARENTERAL-NUTRITION | REHABILITATION | PEDIATRICS | EXPERIENCE | NATURAL-HISTORY | PROGRAM | Multivariate Analysis | United States - epidemiology | Follow-Up Studies | Humans | Risk Factors | Child, Preschool | Infant | Male | Enterocolitis, Necrotizing - epidemiology | Intestinal Diseases - therapy | Canada - epidemiology | Female | Retrospective Studies | Ileocecal Valve | Intestines - transplantation | Parenteral Nutrition | Infant, Newborn | Intestinal Diseases - epidemiology | Cohort Studies | enteral autonomy | short bowel syndrome | Intestinal failure
Pediatrics | MANAGEMENT | SHORT-BOWEL SYNDROME | PEDIATRIC-PATIENTS | ADAPTATION | INFANTS | PARENTERAL-NUTRITION | REHABILITATION | PEDIATRICS | EXPERIENCE | NATURAL-HISTORY | PROGRAM | Multivariate Analysis | United States - epidemiology | Follow-Up Studies | Humans | Risk Factors | Child, Preschool | Infant | Male | Enterocolitis, Necrotizing - epidemiology | Intestinal Diseases - therapy | Canada - epidemiology | Female | Retrospective Studies | Ileocecal Valve | Intestines - transplantation | Parenteral Nutrition | Infant, Newborn | Intestinal Diseases - epidemiology | Cohort Studies | enteral autonomy | short bowel syndrome | Intestinal failure
Journal Article
Infectious Disease Clinics of North America, ISSN 0891-5520, 2014, Volume 28, Issue 2, pp. 237 - 246
Although antimicrobial stewardship has been shown to improve microbiologic susceptibility patterns, decrease drug toxicities, and lower overall drug costs in...
Antimicrobial stewardship | Infection prevention | Antimicrobial resistance | Elderly | Long-term care | URINARY-TRACT-INFECTION | CRITERIA | MORTALITY | INFECTIOUS DISEASES | ANTIBIOTIC USE | IMMUNOLOGY | ASYMPTOMATIC BACTERIURIA | DEFINITIONS | NURSING-HOME RESIDENTS | SURVEILLANCE | OUTCOMES | INTERVENTION | Anti-Bacterial Agents - therapeutic use | Drug Utilization - standards | Bacterial Infections - drug therapy | Long-Term Care - methods | United States | Drug Resistance, Multiple, Bacterial | Humans | Aged, 80 and over | Cost of Illness | Aged | Homes for the Aged | Inappropriate Prescribing - prevention & control | Index Medicus
Antimicrobial stewardship | Infection prevention | Antimicrobial resistance | Elderly | Long-term care | URINARY-TRACT-INFECTION | CRITERIA | MORTALITY | INFECTIOUS DISEASES | ANTIBIOTIC USE | IMMUNOLOGY | ASYMPTOMATIC BACTERIURIA | DEFINITIONS | NURSING-HOME RESIDENTS | SURVEILLANCE | OUTCOMES | INTERVENTION | Anti-Bacterial Agents - therapeutic use | Drug Utilization - standards | Bacterial Infections - drug therapy | Long-Term Care - methods | United States | Drug Resistance, Multiple, Bacterial | Humans | Aged, 80 and over | Cost of Illness | Aged | Homes for the Aged | Inappropriate Prescribing - prevention & control | Index Medicus
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2017, Volume 69, Issue 3, pp. A7 - A8
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2016, Volume 67, Issue 3, pp. A7 - A8
Journal Article
Ophthalmology, ISSN 0161-6420, 2015, Volume 122, Issue 2, pp. 391 - 398.e5
Objective To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of...
Ophthalmology | INTRAVITREAL RANIBIZUMAB | TISSUE-PLASMINOGEN ACTIVATOR | SUBRETINAL HEMORRHAGE | BEVACIZUMAB | PIGMENT EPITHELIAL TEARS | OPHTHALMOLOGY | LARGE SUBMACULAR HEMORRHAGE | CHOROIDAL NEOVASCULAR LESIONS | PNEUMATIC DISPLACEMENT | NATURAL-HISTORY | ENDOTHELIAL GROWTH-FACTOR | Choroidal Neovascularization - diagnosis | Prospective Studies | Follow-Up Studies | Intravitreal Injections | Humans | Male | Wet Macular Degeneration - physiopathology | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Retinal Hemorrhage - diagnosis | Antibodies, Monoclonal, Humanized - administration & dosage | Choroidal Neovascularization - drug therapy | Ranibizumab | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Visual Acuity - physiology | Fluorescein Angiography | Retinal Hemorrhage - physiopathology | Antibodies, Monoclonal, Humanized - therapeutic use | Tomography, Optical Coherence | Treatment Outcome | Choroidal Neovascularization - physiopathology | Wet Macular Degeneration - diagnosis | Wet Macular Degeneration - drug therapy | Aged | Retinal Hemorrhage - drug therapy | Cohort Studies | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy
Ophthalmology | INTRAVITREAL RANIBIZUMAB | TISSUE-PLASMINOGEN ACTIVATOR | SUBRETINAL HEMORRHAGE | BEVACIZUMAB | PIGMENT EPITHELIAL TEARS | OPHTHALMOLOGY | LARGE SUBMACULAR HEMORRHAGE | CHOROIDAL NEOVASCULAR LESIONS | PNEUMATIC DISPLACEMENT | NATURAL-HISTORY | ENDOTHELIAL GROWTH-FACTOR | Choroidal Neovascularization - diagnosis | Prospective Studies | Follow-Up Studies | Intravitreal Injections | Humans | Male | Wet Macular Degeneration - physiopathology | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Retinal Hemorrhage - diagnosis | Antibodies, Monoclonal, Humanized - administration & dosage | Choroidal Neovascularization - drug therapy | Ranibizumab | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Visual Acuity - physiology | Fluorescein Angiography | Retinal Hemorrhage - physiopathology | Antibodies, Monoclonal, Humanized - therapeutic use | Tomography, Optical Coherence | Treatment Outcome | Choroidal Neovascularization - physiopathology | Wet Macular Degeneration - diagnosis | Wet Macular Degeneration - drug therapy | Aged | Retinal Hemorrhage - drug therapy | Cohort Studies | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy
Journal Article
Ophthalmology, ISSN 0161-6420, 2015, Volume 122, Issue 9, pp. 1846 - 1853.e5
Purpose To evaluate the association of subretinal hyperreflective material (SHRM) with visual acuity (VA), geographic atrophy (GA), and scar in the Comparison...
Ophthalmology | OPHTHALMOLOGY | PHOTORECEPTOR LAYER | RISK | VISUAL-ACUITY LOSS | RANIBIZUMAB | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Intravitreal Injections | Tomography, Optical Coherence | Humans | Middle Aged | Geographic Atrophy - physiopathology | Cicatrix - diagnosis | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Retinal Pigment Epithelium | Wet Macular Degeneration - drug therapy | Ranibizumab | Angiogenesis Inhibitors - therapeutic use | Retina - pathology | Visual Acuity - physiology | Fluorescein Angiography | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy
Ophthalmology | OPHTHALMOLOGY | PHOTORECEPTOR LAYER | RISK | VISUAL-ACUITY LOSS | RANIBIZUMAB | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Intravitreal Injections | Tomography, Optical Coherence | Humans | Middle Aged | Geographic Atrophy - physiopathology | Cicatrix - diagnosis | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Retinal Pigment Epithelium | Wet Macular Degeneration - drug therapy | Ranibizumab | Angiogenesis Inhibitors - therapeutic use | Retina - pathology | Visual Acuity - physiology | Fluorescein Angiography | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10077, pp. 1399 - 1409
Summary Background Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials...
Internal Medicine | 3.0 MG | REGRESSION | MEDICINE, GENERAL & INTERNAL | OBESE SUBJECTS | LIFE-STYLE | EXENATIDE | PREVENTION | NORMAL GLUCOSE REGULATION | Type 2 diabetes | Clinical trials | Glucose metabolism | Risk factors | Prediabetic state | Diabetes therapy | Exercise | Obesity | Evaluation | Diabetes mellitus | Health risks | Weight loss | Glucose | Placebo effect | Studies | Weight control | Randomization | Immunology | Classification | Weight reduction | Gastrointestinal surgery | Diabetes | Clinical medicine | Diagnosis | Autoimmune diseases | Risk management
Internal Medicine | 3.0 MG | REGRESSION | MEDICINE, GENERAL & INTERNAL | OBESE SUBJECTS | LIFE-STYLE | EXENATIDE | PREVENTION | NORMAL GLUCOSE REGULATION | Type 2 diabetes | Clinical trials | Glucose metabolism | Risk factors | Prediabetic state | Diabetes therapy | Exercise | Obesity | Evaluation | Diabetes mellitus | Health risks | Weight loss | Glucose | Placebo effect | Studies | Weight control | Randomization | Immunology | Classification | Weight reduction | Gastrointestinal surgery | Diabetes | Clinical medicine | Diagnosis | Autoimmune diseases | Risk management
Journal Article